Short interest for Immunocore Hldgs gives investors a sense of the degree to which investors are betting on the decline of Immunocore Hldgs's stock. Short interest data is updated every two weeks.

Immunocore Hldgs Stock (NASDAQ:IMCR), Short Interest Report

Immunocore Hldgs

Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.

Equities

News

Markets

Analyst Ratings

Trading Ideas

General

IMCR

Immunocore&#39;s Pipeline Is Among The Strongest In Broader Biotech Universe: Analyst

Penny Stocks

Small Cap

Intraday Update

Movers

AIMD

ALLO

ANGO

APLT

ATXI

AXGN

BNZI

CISO

CPRX

CYCC

DRMA

ELAN

EXAI

Intelligent Bio Solutions Inc. - Common Stock

INBS

KORE

KRUS

LSDI

NEXI

OMGA

PNST

PTON

PYPD

RCAC

SABS

SMFL

SWVL

TBPH

VERB

VYGR

Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Analyst Color

Biotech

Health Care

Price Target

Initiation

Needham has initiated coverage on Immunocore Holdings Plc (NASDAQ: IMCR) with a Buy rating and 

Cancer Focused Immunocore Leads The Way In TCR Therapeutics, Positioned For Success: Analyst Says

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings PLC

Pfizer Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) is&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38595739/pfizer-prospects-garner-mixed-sentiment-from-analysts-finally-the-pivot-investors-h" rel="noreferrer noopener">looking to build</a>&nbsp;on the success of its&nbsp;COVID-19&nbsp;vaccine rollout by introducing a direct-to-consumer medicines platform under the brand &#8220;Pfizer for All.&#8221;&nbsp;
The move, reflected in a recent trademark application, aims to provide medical information, mail-order pharmacy, and telehealth&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38554240/pfizer-embraces-direct-to-consumer-model-for-covid-antiviral-says-comirnaty-revenues-continue-to-" rel="noreferrer noopener">services to US patients</a>.
Recent reports indicate Pfizer&#8217;s intention to include various medications, including its&nbsp;COVID&nbsp;antiviral Paxlovid and diagnostic kits, on the platform later this year, expanding its offerings to cater to diverse healthcare needs.
Related:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38710835/pfizer-agrees-to-settle-over-10-000-lawsuits-about-cancer-risks-associated-with-discontinued-hear" rel="noreferrer noopener">Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac</a>.
The platform will offer a &#8220;downloadable mobile application for providing medical information&#8221; as well as &#8220;mail order pharmacy services&#8221; and &#8220;diagnostic test kits . . . for use in disease screening and detection&#8221;, according to the trademark application, the&nbsp;<a target="_blank" href="https://www.ft.com/content/772794b4-0dd8-4ba1-a356-bc5f33c21589" rel="noreferrer noopener">FT writes</a>.
This initiative follows similar endeavors in the pharmaceutical industry to bypass traditional&nbsp;middlemen&nbsp;and directly reach consumers.&nbsp;
Earlier this year,&nbsp;Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) launched its LillyDirect platform,&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36495250/eli-lilly-launches-website-to-help-patients-with-home-delivery-options-for-weight-loss-medicines" rel="noreferrer noopener">marking an industry first</a>.
The &#8220;Pfizer for All&#8221; platform is positioned as a healthcare equity endeavor, seeking to simplify the often convoluted process through which US patients obtain their medications, the Financial Times highlights.&nbsp;
Citing the sources familiar with the plans, the FT&nbsp;<a target="_blank" href="https://www.ft.com/content/772794b4-0dd8-4ba1-a356-bc5f33c21589" rel="noreferrer noopener">notes</a>&nbsp;that Pfizer intends to leverage its brand equity gained from its pivotal role in combating the Covid-19 crisis.
Despite Pfizer&#8217;s favorable reception during the height of the vaccine rollout, its favorability score has experienced fluctuations. The company&#8217;s stock value has also declined from its pandemic peak, facing skepticism from investors regarding its growth trajectory.
However, Timothy Mackey, a professor of global health at the University of California San Diego, believes that Pfizer&#8217;s approach may resonate positively with consumers despite mixed sentiments surrounding pharmaceutical companies.&nbsp;
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38708473/second-death-pfizer-reports-young-boys-death-after-one-year-of-gene-therapy-treatment-in-muscle-w" rel="noreferrer noopener">Second Death &#8211; Pfizer Reports Young Boy&#8217;s Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial</a>.
Price Action: PFE shares are up 1.30% at $28.38 at last check Monday.
Photo via Shutterstock

Pfizer Follows Eli Lilly's Footsteps To Sell Medicines Directly To Patients

House members recently <a href="https://www.benzinga.com/markets/cannabis/24/05/38764797/vermont-gov-scott-opposes-drug-safe-consumption-sites-virginias-cannabis-surveillance-system-and">approved</a> the Senate measure, that seeks to set up an eight-person psychedelic-assisted therapy working group, with amendments. Vermont Senators gave the green light to the revised language of the bill on Friday, approving changes previously made in the state House of Representatives.
The bill, S.114, from Sen. Martine Larocque Gulick (D) was first passed in the Senate, before the amendments in the House would &#8220;review the latest research and evidence of the public health benefits and risks of clinical psychedelic-assisted treatments&#8221; and &#8220;examine the laws and programs of other states that have authorized the use of psychedelics by health care providers in a therapeutic setting.&#8221;
Sen. Larocque Gulick was not pleased with the changes made by the House members as the bill would not change the legal status of any substances, <a href="https://www.marijuanamoment.net/vermont-lawmakers-send-revised-psychedelic-assisted-therapy-task-force-bill-to-governor/">reported</a> Marijuana Moment.
"Personally, I'm very disappointed that they took out the conversation about decriminalization," Sen. Larocque Gulick said on Friday. "I mean, this is literally a group that's just going to be talking and looking at data and researching."
The bill is now heading to the Gov. Phil Scott's (R) desk.
Meanwhile, in Alaska, the state Senate members on Friday approved a House-passed measure to set up a task force with the goal of studying how to license and regulate psychedelic-assisted therapy. That is if substances like MDMA and psilocybin are approved on the federal level
Following an 18-1 vote by the chamber's members, the measure is up for review by Gov. Mike Dunleavy (R).
Sponsored by Jennie Armstrong (D), HB 228, like Vermont's measure, would not affect the legal status of drugs in Alaska, <a href="https://www.marijuanamoment.net/alaska-bill-to-create-task-force-to-study-psychedelic-assisted-therapy-heads-to-governors-desk/">reported</a> Marijuana Moment.
The deadline for the group to submit the report is on or before January 31, 2025.

Cannabis

Government

Psychedelics

Regulations

Politics

GOP Governors In Vermont And Alaska To Weigh In On Psychedelic-Assisted Therapy Task Force Bills

The Bill &amp; Melinda Gates Foundation is about to lose one of its namesakes. Co-chair of the foundation&#8217;s multibillion-dollar endowment, Melinda French Gates, announced on Monday that she will resign from the role. Alongside her ex-husband and Microsoft co-founder Bill Gates, she has helped lead <a href="https://www.benzinga.com/topic/bill-and-melinda-gates-foundation">the charitable foundation</a>.
What Happened: French Gates first <a href="https://twitter.com/melindagates/status/1790049411227086949?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet">announced</a> on the social media platform X that she was resigning from her position to pursue her own philanthropic projects. French Gates has held the role since 2000.
&#8220;I am immensely proud of the foundation that Bill and I built together and the extraordinary work it is doing to address inequalities around the world. I care deeply about the foundation team, our partners around the world, and everyone who is touched by its work,&#8221; French Gates said on X. She will officially step down on June 7.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://t.co/JYIovjNYKo">pic.twitter.com/JYIovjNYKo</a>
&mdash; Melinda French Gates (@melindagates) <a href="https://twitter.com/melindagates/status/1790049411227086949?ref_src=twsrc%5Etfw">May 13, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
French Gates announced as part of her agreement to leave the foundation, she would receive an additional $12.5 billion for philanthropic efforts on behalf of women and families.
&#8220;This is a critical moment for women and girls in the U.S. and around the world — and those fighting to protect and advance equality are in urgent need of support,&#8221; French Gates said.
French Gates and her husband announced their separation in 2021. 
Bill Gates followed up with a <a href="https://twitter.com/BillGates/status/1790049639330402416">statement</a> on X: &#8220;I am sorry to see Melinda leave, but I am sure she will have a huge impact in her future philanthropic work,&#8221; he said.
Why it Matters: The Bill &amp; Melinda Gates Foundation has an endowment of $75.2 billion as of December 2023, <a href="https://www.gatesfoundation.org/about/foundation-fact-sheet">according</a> to the foundation. The organization has served as the center of Bill Gates&#8217; multi-billion dollar philanthropic efforts. Warren Buffett, CEO of Berkshire Hathaway, also contributed $36.2 billion through 2022, <a href="https://www.gatesfoundation.org/about/leadership/warren-buffett">according</a> to the foundation.
The foundation has several initiatives including gender equality, global health and global infrastructural development, says its website.
Photo: Courtesy USAID Agency, MomAndBaby, via<a href="https://www.flickr.com/photos/usaid_images/14326539268/in/photolist-nPZfZJ-2hfn9eJ-crj4d5-pFoANR-FpU9Cd-PoJQtr-g8LvJd-poWyEU-cCZV1b-8L7gCu-Nate54-Mu9phz-KaP2qq-pcaKc7-BBeihF-q6SvXu-ccHHvQ-cNPTdb-k9fF6-4S1RoF-2ntJY7t-DsT7vu-mHnK1p-2ntQdGV-2otjLGg-4S62LA-2otarQq-9UsxcC-8L7HjW-SbS49w-2kpo68J-2hphu1z-2n28Pfm-2f391fh-2ntQgxm-pWfiz2-VuRNjr-2hphuhX-x1utEz-cvMNWA-bfBSDa-6tqC6b-ToxvBG-2kpoDzD-6tqBNs-fBkYSY-2ot87Lk-2kpjf3H-pRzZT9-bwNW3K"> Flickr </a>Creative Commons

Movers & Shakers

Management

Melinda French Gates To Resign As Gates Foundation Co-Chair, Plans To Continue Her Own Philanthropic Work: What You Need to Know

Keith Gill, also known as Roaring Kitty, sent the <a href="https://www.benzinga.com/news/24/05/38789404/gamestops-rally-resumes-in-may-what-sparked-the-interest">meme stock community into a frenzy </a>Sunday night, posting for the first time in almost three years on X, formerly Twitter. The post, a simple meme of a gamer moving forward in his chair, was enough to send GameStop Corp's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) stock higher by more than 100% at one point Monday, <a href="https://www.benzinga.com/news/24/05/38789404/gamestops-rally-resumes-in-may-what-sparked-the-interest">adding billions of dollars in valuation to the video game company. </a>But Gill wasn't done after Sunday's post. On Monday, he continued to share more content on X, posting several videos each filled with pop-culture references. Highlights include a mashup of Thanos from The Avengers and Hugh Jackman's &#8220;<a href="https://x.com/TheRoaringKitty/status/1790034263603139012">X-Men</a>,&#8221; Ferris Bueller and a<a href="https://x.com/TheRoaringKitty/status/1790041813379850491"> cat</a>, and clips from &#8220;Game of <a href="https://x.com/TheRoaringKitty/status/1790049362846117942">Thrones</a>.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://t.co/8YSKm1N3IJ">pic.twitter.com/8YSKm1N3IJ</a>
&mdash; Roaring Kitty (@TheRoaringKitty) <a href="https://twitter.com/TheRoaringKitty/status/1790049362846117942?ref_src=twsrc%5Etfw">May 13, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Another post from Gill featured clips from, &#8220;The Avengers.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://t.co/fGJPsi20DI">pic.twitter.com/fGJPsi20DI</a>
&mdash; Roaring Kitty (@TheRoaringKitty) <a href="https://twitter.com/TheRoaringKitty/status/1790079562866360327?ref_src=twsrc%5Etfw">May 13, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Also: <a href="https://www.benzinga.com/general/education/24/05/38793704/who-is-roaring-kitty-why-does-his-return-to-social-media-matter-for-gamestop-stock">Who Is Roaring Kitty? Why Does His Return To Social Media Matter For GameStop Stock?</a>
Cryptic social media posts are seemingly a staple of the meme stock frenzy, with Ryan Cohen able to move stocks by posting undecipherable memes in the past, like a picture of an ice cream cone which sent GameStop's stock up more than 100% in 2021.&nbsp;
GameStop, which famously surged more than 3000% amid a short squeeze in late 2020 and early 2021, has struggled since the spike and traded down more than 80% from its highs before Monday's gain. Gill was one of the key drivers of the short squeeze, posting his investment thesis on Reddit Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) WallStreet Bets and encouraged retail investors to buy the stock which he saw as extremely undervalued.&nbsp;
When Gill posted his first video Monday, GameStop's stock spiked another 5% to right around the $30 level. While the stock is still up more than 70% in Monday's session, it has retreated from its Monday morning highs, falling around 20%. Other so-called ‘meme stocks' such as AMC Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) and KOSS Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOSS#NASDAQ">KOSS</a>), also spiked higher Monday, trading up by more than 40% and 20% respectively. 
Traders and investors should be aware that increased volatility could make investments in these stocks riskier, but if history is any indication of what's to come, there could be more in store for highly-shorted names as retail interest picks up.&nbsp;
Now Read: <a href="https://www.benzinga.com/news/24/05/38796280/is-roaring-kitty-back-for-round-2-gamestop-posts-flood-wallstreetbets-as-traders-eye-massive-gains-w">Is Roaring Kitty Back For Round 2? GameStop Posts Flood WallStreetBets As Traders Eye Massive Gains: &#8216;We Are So Back&#8217;</a>
Photo: Shutterstock

Gaming

Social Media

KOSS

RDDT

Roaring Kitty Doubles Down, Posts New Videos On X Sending GameStop's Stock Higher

WIIM

Novo Nordisk shares are trading higher after the company announced the FRONTIER 2 trial achieved its co-primary endpoints.

Barclays analyst Tim Long maintains Ubiquiti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) with a Underweight and raises the price target from $93 to $108.

Barclays Maintains Underweight on Ubiquiti, Raises Price Target to $108

Investors with a lot of money to spend have taken a bullish stance on Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PANW, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 29 uncommon options trades for Palo Alto Networks.
This isn't normal.
The overall sentiment of these big-money traders is split between 58% bullish and 24%, bearish.
Out of all of the special options we uncovered, 11 are puts, for a total amount of $494,402, and 18 are calls, for a total amount of $1,142,752.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $195.0 to $400.0 for Palo Alto Networks over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Palo Alto Networks's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Palo Alto Networks's whale activity within a strike price range from $195.0 to $400.0 in the last 30 days. 
<h3>Palo Alto Networks 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715624155_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PANW</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/31/24</td>
<td>$19.0</td>
<td>$17.85</td>
<td>$18.5</td>
<td>$300.00</td>
<td>$183.1K</td>
<td>529</td>
<td style="text-align: right;">140</td>
</tr>
<tr>
<td>PANW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/31/24</td>
<td>$17.85</td>
<td>$17.5</td>
<td>$17.5</td>
<td>$300.00</td>
<td>$178.5K</td>
<td>529</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>PANW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/31/24</td>
<td>$17.15</td>
<td>$16.8</td>
<td>$16.8</td>
<td>$300.00</td>
<td>$168.0K</td>
<td>529</td>
<td style="text-align: right;">247</td>
</tr>
<tr>
<td>PANW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$23.25</td>
<td>$21.45</td>
<td>$21.45</td>
<td>$250.00</td>
<td>$130.8K</td>
<td>1.3K</td>
<td style="text-align: right;">129</td>
</tr>
<tr>
<td>PANW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$10.4</td>
<td>$8.75</td>
<td>$9.05</td>
<td>$295.00</td>
<td>$90.5K</td>
<td>1.5K</td>
<td style="text-align: right;">101</td>
</tr>
</tbody>
</table>

<h3>About Palo Alto Networks</h3>
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 85,000 customers across the world, including more than three fourths of the Global 2000.
Following our analysis of the options activities associated with Palo Alto Networks, we pivot to a closer look at the company's own performance.
<h3>Where Is Palo Alto Networks Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,242,345, the price of PANW is up by 1.46%, reaching $301.82.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 7 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Palo Alto Networks</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $345.0.
<ul>
<li>An analyst from Oppenheimer persists with their Outperform rating on Palo Alto Networks, maintaining a target price of $330. </li>
<li>An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $350. </li>
<li>An analyst from Keybanc persists with their Overweight rating on Palo Alto Networks, maintaining a target price of $355. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Palo Alto Networks options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

PANW

Palo Alto Networks Unusual Options Activity

Whales with a lot of money to spend have taken a noticeably bullish stance on ZIM Integrated Shipping.
Looking at options history for ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) we detected 24 trades.
If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish expectations and 29% with bearish.
From the overall spotted trades, 11 are puts, for a total amount of $523,736 and 13, calls, for a total amount of $653,972.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $10.0 to $30.0 for ZIM Integrated Shipping over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in ZIM Integrated Shipping's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to ZIM Integrated Shipping's substantial trades, within a strike price spectrum from $10.0 to $30.0 over the preceding 30 days.
<h3>ZIM Integrated Shipping Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715624150_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZIM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$2.55</td>
<td>$2.22</td>
<td>$2.31</td>
<td>$18.00</td>
<td>$138.6K</td>
<td>5.7K</td>
<td>4.3K</td>
</tr>
<tr>
<td>ZIM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$12.85</td>
<td>$12.8</td>
<td>$12.83</td>
<td>$30.00</td>
<td>$89.9K</td>
<td>15</td>
<td>273</td>
</tr>
<tr>
<td>ZIM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$1.56</td>
<td>$1.41</td>
<td>$1.56</td>
<td>$17.50</td>
<td>$77.8K</td>
<td>2.5K</td>
<td>673</td>
</tr>
<tr>
<td>ZIM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.2</td>
<td>$7.15</td>
<td>$7.15</td>
<td>$12.50</td>
<td>$74.3K</td>
<td>5.8K</td>
<td>226</td>
</tr>
<tr>
<td>ZIM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$13.0</td>
<td>$12.75</td>
<td>$12.84</td>
<td>$30.00</td>
<td>$70.4K</td>
<td>15</td>
<td>507</td>
</tr>
</tbody>
</table>

<h3>About ZIM Integrated Shipping</h3>
ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.
After a thorough review of the options trading surrounding ZIM Integrated Shipping, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>ZIM Integrated Shipping's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 6,181,491, the ZIM's price is up by 1.19%, now at $17.8. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 8 days.</li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest ZIM Integrated Shipping options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

ZIM Integrated Shipping Options Trading: A Deep Dive into Market Sentiment

Deep-pocketed investors have adopted a bearish approach towards Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in FOUR usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Shift4 Payments. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 62% bearish. Among these notable options, 5 are puts, totaling $253,857, and 3 are calls, amounting to $118,648.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $57.5 and $70.0 for Shift4 Payments, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Shift4 Payments's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Shift4 Payments's whale activity within a strike price range from $57.5 to $70.0 in the last 30 days. 
<h3>Shift4 Payments Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1715624145_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOUR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$0.95</td>
<td>$0.9</td>
<td>$0.9</td>
<td>$57.50</td>
<td>$69.1K</td>
<td>156</td>
<td>1.3K</td>
</tr>
<tr>
<td>FOUR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$1.05</td>
<td>$1.0</td>
<td>$1.0</td>
<td>$57.50</td>
<td>$53.1K</td>
<td>156</td>
<td>539</td>
</tr>
<tr>
<td>FOUR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$6.1</td>
<td>$5.8</td>
<td>$6.1</td>
<td>$67.50</td>
<td>$45.7K</td>
<td>6.6K</td>
<td>200</td>
</tr>
<tr>
<td>FOUR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$14.7</td>
<td>$14.1</td>
<td>$13.9</td>
<td>$60.00</td>
<td>$43.1K</td>
<td>58</td>
<td>31</td>
</tr>
<tr>
<td>FOUR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$4.6</td>
<td>$3.3</td>
<td>$4.3</td>
<td>$70.00</td>
<td>$43.0K</td>
<td>339</td>
<td>100</td>
</tr>
</tbody>
</table>

<h3>About Shift4 Payments</h3>
Shift4 Payments Inc is provider of integrated payment processing and technology solutions. The company offers software providers a single integration to an end-to-end payments offering, a powerful gateway and a robust suite of technology solutions (including cloud enablement, business intelligence, analytics, and mobile) to enhance the value of their software suites and simplify payment acceptance. The company derives maximum revenue from United States.
Following our analysis of the options activities associated with Shift4 Payments, we pivot to a closer look at the company's own performance.
<h3>Shift4 Payments's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 1,009,703, the FOUR's price is up by 1.14%, now at $65.83. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 80 days.</li>
</ul>
<h3>Expert Opinions on Shift4 Payments</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $79.0.
<ul>
<li>An analyst from Benchmark has revised its rating downward to Buy, adjusting the price target to $99. </li>
<li>Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Shift4 Payments, targeting a price of $66. </li>
<li>Maintaining their stance, an analyst from Mizuho continues to hold a Buy rating for Shift4 Payments, targeting a price of $75. </li>
<li>Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Shift4 Payments, targeting a price of $75. </li>
<li>An analyst from Goldman Sachs persists with their Buy rating on Shift4 Payments, maintaining a target price of $80. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Shift4 Payments, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

FOUR

Shift4 Payments Unusual Options Activity

The return of a social media legend has sparked a frenzy in the cryptocurrency world, with <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38796814/gamestop-stock-pumped-but-what-about-the-gamestop-meme-coin-its-gonna-get-wild-predicts-tr">memecoins referencing him</a> surging in value.
What Happened: Keith Gill, better known online as &#8220;Roaring Kitty,&#8221; was a key figure in the 2021 meme stock rally, targeting companies like GameStop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) with his online activity.
After a long hiatus, Gill&#8217;s return to social media sent shockwaves through the financial world, with a new cryptocurrency named after Roaring Kitty (ROAR) seeing a staggering 1400% increase <a href="https://www.coingecko.com/en/coins/roaring-kitty">according</a> to CoinGecko data.
This particular coin, despite having no affiliation with the company, capitalized on the hype surrounding Gill&#8217;s return.
Gill&#8217;s return wasn&#8217;t just felt in the world of traditional finance. 
The meme coin market, known for its volatility and ties to social media trends, responded with a surge in memecoins referencing both Gill and GameStop.
These meme coins, easily created and traded, can experience massive price fluctuations due to their small size and limited availability.
One such memecoin, simply called (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">GME</a>) is currently <a href="https://www.coingecko.com/en/coins/gme">valued</a> at $0.010.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38794260/arthur-hayes-major-economies-to-print-even-more-money-in-the-next-24-months">Arthur Hayes: &#8216;Major Economies To Print Even More Money&#8217; In The Next 24 Months</a>
Why It Matters: The demand for meme coins has been steadily rising since late February, as investors flush with cash from established cryptocurrencies like Bitcoin and Ether look for new opportunities.
This trend mirrors the events of early 2021, when meme coins like Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) skyrocketed in value after endorsements from celebrities like Elon Musk.
The enthusiasm over Roaring Kitty was palpable on social media, with Twitter user Mike Schmidt <a href="https://x.com/MikeSchmidt1111/status/1790051578239476122">commenting</a>, &#8220;Imagine fading a Roaring Kitty coin on the biggest shitter chain during a cat szn with the GME legend back as the main character. Man this is fuckin hilarious.&#8221; 
Similarly, the official wallstreetbets Twitter account <a href="https://x.com/wallstreetbets/status/1790029319525257392">shared</a>, &#8220;My life savings is in the hands of a man that calls himself Roaring Kitty and I could not be more comfortable .&#8221;
Crypto enthusiasts and traders are keenly observing these developments. 
<a href="https://x.com/0xgaut/status/1790039820930003332">According</a> to Gaut, Roaring Kitty gained nearly 200,000 followers shortly after his post, suggesting a strong market reaction.
This sentiment was <a href="https://x.com/SizeChad/status/1790030162655953002">echoed</a> by Size Chad, who linked the event to increased trading volumes on Robinhood, noting their partnership with Arbitrum.
Furthermore, Crypto Tea <a href="https://x.com/CryptoTea_/status/1790038567122579810">highlighted </a>the broader implications of such movements, tweeting, &#8220;Roaring kitty posts a meme and $1 billion gets liquidated. Future of finance.&#8221; 
These events demonstrate the growing intersection between cryptocurrency and traditional financial markets, driven largely by community engagement and speculation.
What&#8217;s Next: As the community gears up for the Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19, these developments will likely be a hot topic.
The event will delve into how digital assets are reshaping finance, influenced by social media and community-driven investment trends. Discussions will also cover the regulatory landscape that is struggling to keep pace with these rapid changes, ensuring a comprehensive dialogue on the future of finance in the era of <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38706497/bitcoin-etf-issuer-vaneck-launches-memecoin-index-includes-doge-shib-and-4-more-meme-coins">meme stocks and cryptocurrencies.</a>
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38793991/why-grayscale-could-be-the-spark-eth-needs-10x-research">Why Grayscale Could Be The Spark ETH Needs: 10x Research</a>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$GME

Keith Gill's 'Roaring Kitty' Comeback Sparks 1400% Surge Of Kitty-Themed Meme Coin

Barclays analyst Peter Arment maintains TransDigm Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) with a Overweight and raises the price target from $1250 to $1500.

Barclays Maintains Overweight on TransDigm Gr, Raises Price Target to $1500

Barclays analyst Nicholas Campanella maintains Pinnacle West Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>) with a Overweight and raises the price target from $76 to $81.

Barclays Maintains Overweight on Pinnacle West Capital, Raises Price Target to $81

Amprius Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) shares are trading lower by 30.5% to $1.37 during Monday&#8217;s session after the company announced it is offering a temporary deal for holders of its public and private warrants to exercise them for cash at a <a href="https://www.benzinga.com/pressreleases/24/05/b38787739/amprius-announces-temporary-offer-allowing-public-and-private-warrants-to-be-exercised-at-a-reduce">reduced price</a>.
This offer applies to specific amounts of shares and allows holders to exercise their warrants at $1.10 each, down from the usual $11.50. The offer expires on June 11, and aims to boost cash exercise of the warrants to provide funding for Amprius&#8217; working capital and development plans. 
If all warrants are exercised at the reduced price, Amprius stands to receive approximately $50 million in gross proceeds.
See Also: <a href="https://www.benzinga.com/news/24/05/38796280/is-roaring-kitty-back-for-round-2-gamestop-posts-flood-wallstreetbets-as-traders-eye-massive-gains-w">Is Roaring Kitty Back For Round 2? GameStop Posts Flood WallStreetBets As Traders Eye Massive Gains: &#8216;We Are So Back&#8217;</a>
<h2 class="wp-block-heading">Should I Sell My AMPX Stock?</h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Amprius Technologies have decreased by 83.63% in the past year. An investor who bought shares of Amprius Technologies at the beginning of the year would take a loss of $2.58 per share if they sold it today. The stock has fallen 20.25% over the past month, meaning an investor who bought shares on Apr. 1 would see a capital loss of $0.96.
Amprius Technologies shares have an all-time high of $12.94, representing 811.59% upside from current levels.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Amprius Technologies stock currently has an RSI of 43.73, indicating neutral conditions.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a>
AMPX has a 52-week high of $10.63 and a 52-week low of $1.27.

AMPX

Why Amprius Technologies (AMPX) Shares Are Falling

Barclays analyst Derek Podhaizer maintains Ormat Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORA#NYSE">ORA</a>) with a Equal-Weight and lowers the price target from $75 to $73.

Barclays Maintains Equal-Weight on Ormat Technologies, Lowers Price Target to $73

Barclays analyst Brandon Oglenski maintains Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) with a Overweight and lowers the price target from $305 to $275.

Barclays Maintains Overweight on Norfolk Southern, Lowers Price Target to $275

Barclays analyst Benjamin Theurer maintains Mosaic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) with a Overweight and lowers the price target from $42 to $39.

Barclays Maintains Overweight on Mosaic, Lowers Price Target to $39

Marijuana workers at a Nabis warehouse in California voted overwhelmingly to unionize by joining Teamsters Local 630. Nabis is a California-based licensed cannabis wholesale platform. These 84 new Teamsters are employed as drivers and warehouse workers. 
"We are dedicated to ensuring stability and ending exploitation in the rapidly growing cannabis industry," stated Lou Villalvazo, secretary-treasurer at Local 630 in Los Angeles. "Organizing and empowering workers is the key to fostering their growth into the middle class. Through solidarity and commitment, we will make these good middle-class jobs!"
Established in 1937, Teamsters Local 630 represents workers in various industries, from clerical, warehouse, professional drivers, food service, liquor, food processing,&nbsp;dairy and more.&nbsp;
Employees at Nabis filed for the election on April 20, the internationally renowned cannabis holiday. They are the third group of cannabis workers to join the Teamsters in three weeks and the third group at the company to join the union.
"Cannabis workers are becoming Teamsters at a break-neck pace because we fight hard and win strong contracts," Peter Finn, Teamsters Western Region International VP and Food Processing Division director said in a statement. "We look forward to doing the same thing for these workers.&#8221;
As the industry develops, more employees join unions&nbsp;and&nbsp;cannabis workers conditions are changing. If you are curious to learn all about the future of the cannabis industry, join us at the Benzinga Cannabis Capital Conference&nbsp;this October in Chicago. Hear directly from key industry players, experts, advocates, and policymakers. Get your tickets now by following&nbsp;<a target="_blank" href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" rel="noreferrer noopener">this link</a>.&nbsp;
Jonathan Misquez, a warehouse associate at Nabis, commented,&nbsp;"The reason&nbsp;that I&nbsp;organized was to have a voice at Nabis, not only for myself but for my coworkers.&nbsp;"My coworkers have really helped me through a lot and taught me so much on and off the clock, so I wanted to help them receive a contract that reflects the hard work they put in every day. Iron sharpens iron, every&nbsp;day&nbsp;we&nbsp;all make each other better and&nbsp;together&nbsp;we proved that we are united.&#8221;
Over the last several years, Teamsters have been pushing hard to unionize workers in the nascent cannabis industry. Recent unionizing efforts were undertaken across the country at major companies in 2023, including, the cannabis Company (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CBSTF#OTCQX">CBSTF</a>) in <a href="https://www.benzinga.com/markets/cannabis/24/05/38669949/cannabis-workers-in-l-a-join-teamsters-to-improve-pay-working-conditions-and-have-a-voice" target="_blank" rel="noreferrer noopener">California</a>, Cresco Labs <a href="https://www.benzinga.com/quote/crlbf" target="_blank" rel="noreferrer noopener">CRLBF</a>in <a href="https://www.benzinga.com/markets/cannabis/24/05/38585820/teamsters-unionize-cannabis-workers-at-another-cresco-labs-dispensary-in-illinois-it-feels-good" target="_blank" rel="noreferrer noopener">Illinois</a>, Grassdoor in <a href="https://www.benzinga.com/markets/cannabis/23/03/31477358/workers-at-two-more-cannabis-companies-unionize-with-teamsters-and-ufcw" target="_blank" rel="noreferrer noopener">California</a>, and Verano Holdings Corp <a href="https://www.benzinga.com/quote/vrnof" target="_blank" rel="noreferrer noopener">VRNOF in</a> <a href="https://www.benzinga.com/markets/cannabis/22/08/28566870/veranos-firing-of-union-supporters-flops-zen-leaf-chicago-workers-join-teamsters-local-777" target="_blank" rel="noreferrer noopener">Chicago</a>.
Related links:&nbsp;
<a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/03/38003989/eaze-cannabis-delivery-drivers-in-sacramento-join-teamsters-local-150" rel="noreferrer noopener">Eaze Cannabis Delivery Drivers In Sacramento Join Teamsters Local 150</a>
<a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/04/38220799/nabis-logistics-platform-helps-california-cannabis-brands-grow-these-two-operators-join-rooster" rel="noreferrer noopener">Nabis Logistics Platform Helps California Cannabis Brands Grow, These&nbsp;Two Operators Join Rooster</a>
Photo: Benzinga edit with images by lexandros Michailidisand Oleksandrum via Shutterstock

THE CANNABIST CO HLDG by THE CANNABIST COMPANY HOLDINGS INC.

CBSTF

84 Cannabis Warehouse Workers And Drivers In California Join Teamsters For Contracts Reflecting Their 'Hard Work'

Inventiva&nbsp;SA&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) announced the&nbsp;publication&nbsp;in the peer-reviewed scientific journal&nbsp;Nature Communications&nbsp;of additional results from its NATIVE Phase 2b trial demonstrating the improvement of markers of cardiometabolic health in patients with MASH/NASH&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/g38781778/inventiva-announces-the-publication-in-nature-communications-of-additional-results-from-native-pha" rel="noreferrer noopener">treated with&nbsp;lanifibranor</a>.
Following lanifibranor treatment, the trial demonstrated significant improvement in patients with metabolic dysfunction-associated steatohepatitis (MASH)/ non-alcoholic steatohepatitis (NASH) with and without Type 2 Diabetes and with or without obesity of markers of cardiometabolic health.
In February, Inventiva announced it stopped enrolling new patients in the NATiV3 Phase 3 trial for lanifibranor in NASH due to a reported&nbsp;serious&nbsp;adverse reaction. This reaction involved elevated liver enzymes in a&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/37182374/why-is-liver-disease-focused-inventiva-stock-trading-lower-today" rel="noreferrer noopener">patient undergoing treatment</a>.
Lanifibranor treatment also led to lower fasting glucose to normal levels in 71% of patients with MASH/NASH and prediabetes treated with the 1200mg dose and 67% of patients treated with the 800mg dose versus 11% of patients on placebo.
In addition, no patients treated with either dose of&nbsp;lanifibranor&nbsp;with MASH/NASH and normoglycemia at baseline progressed to prediabetes at week 24, versus 26% of patients in the placebo arm.
Furthermore, 38% and 44% of patients with MASH/NASH and high cardiovascular risk treated with 1200mg and 800mg of lanifibranor, respectively, improved to intermediate or low cardiovascular risk at week 24.
44% and 35% of patients at intermediate risk improved to low risk when treated with 1200mg and 800mg of lanifibranor, respectively. However, in the placebo arm, only 26% of patients at high cardiovascular risk improved to intermediate, .2q&nbsp; &nbsp;and&nbsp;13% improved from intermediate to low cardiovascular risk.
The weight gain observed in a portion of the patient population treated with lanifibranor was shown to be associated with improvement of all markers of cardiometabolic health,&nbsp;similarly&nbsp;to patients treated with lanifibranor&nbsp;who&nbsp;maintained a stable weight throughout the study.&nbsp;
This finding contrasts the weight gain observed in patients on placebo, which was associated with worsening cardiometabolic markers.&nbsp;
In addition, the increase in adiponectin (helps insulin sensitivity and inflammation) levels following treatment with 1200mg and 800mg of lanifibranor occurred in 95% and 86% of patients, respectively, versus only 10% of patients in the placebo arm.&nbsp;
The increase in adiponectin level at week 24 was correlated with improvement of markers of insulin resistance, glycemic control, lipid metabolism, and steatosis, as well as hs-CRP, aminotransferases, and improvement in liver histological endpoints for disease activity and fibrosis.
Price Action:&nbsp;IVA shares are up 5.62% at $3.57 at last check Monday.

Why Is Inventiva's Stock Trading Higher on Monday?

Barclays analyst Tom O'Malley maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Overweight and raises the price target from $120 to $145.

Barclays Maintains Overweight on Micron Technology, Raises Price Target to $145

Barclays analyst Trevor Young maintains MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) with a Overweight and raises the price target from $1800 to $2000.

MELI

Barclays Maintains Overweight on MercadoLibre, Raises Price Target to $2000

Immunocore GAAP EPS of -$0.49 misses by $0.13, revenue of $70.5M beats by $1.32M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Immunocore Hldgs (NASDAQ:<a href="https://investorplace.com/stock-quotes/imcr-stock-quote/">IMCR</a>) just reported results for the first quarter of 2024.<ul><li>Immunocore Hldgs reported earnings per share of -49 cents. This was below the analyst estimate for EPS of -36 cents.</li><li>The company reported revenue of $70.50 million.</li><li>This was 0.91% worse than the analyst estimate for revenue of $71.15 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/imcr-stock-earnings-immunocore-hldgs-for-q1-of-2024/">IMCR Stock Earnings: Immunocore Hldgs Misses EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

IMCR Stock Earnings: Immunocore Hldgs Misses EPS, Misses Revenue for Q1 2024

Needham analyst Gil Blum has maintained their bullish stance on IMCR stock, giving a Buy rating on May 2. Gil Blum has given his Buy rating due to ...

Immunocore Holdings Outperforms with Kimmtrak Sales Surpassing Estimates; Maintains Buy Rating

Naureen Quibria, an analyst from Capital One Financial, reiterated the Buy rating on Immunocore Holdings (IMCR – Research Report). The associated p...

Buy Rating for Immunocore Holdings on Strong Financials and Expanding Innovative Pipeline

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Immunocore Holdings (IMCR – Research Report), with a price target...

Barclays Remains a Buy on Immunocore Holdings (IMCR)

Immunocore Holdings (IMCR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst William Maug...

Immunocore Holdings: A Balanced Hold Rating Amid Anticipated Clinical Updates

Oppenheimer analyst Jeff Jones maintained a Buy rating on Immunocore Holdings (IMCR – Research Report) today and set a price target of $87.00. The ...

Oppenheimer Reaffirms Their Buy Rating on Immunocore Holdings (IMCR)

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Immunocore Holdings (IMCR – Research Report), boosting the price target to $...

Buy Rating Affirmed for Immunocore Holdings on Strong KIMMTRAK Sales and Promising Pipeline Growth

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tango Therapeutics (TNGX – Research Report), Aclar...

Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Aclaris Therapeutics (ACRS) and Immunocore Holdings (IMCR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Immunocore Holdings (IMCR – Research Report), Warb...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Immunocore Holdings (IMCR), Warby Parker (WRBY) and Ocular Therapeutix (OCUL)

ACRS

OCUL

TNGX

WRBY

Press Releases

Immunocore Prices Upsized Convertible Senior Notes Offering

DELFI Diagnostics Announces Availability of New Fragmentome-Based Cancer Treatment Monitoring Assay

Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Immunocore Hldgs Stock (NASDAQ:IMCR), Short Interest Report

People Also Watch